The biological nature of LCIS and its relationship to invasive cancers is controversial. The multicentricity of the disease has led some authors to propose that it is a hyperplastic rather than a neoplastic process. Some authorities regard LCIS as a risk indicator for invasive cancer or a morphological marker of a carcinogenic stimulus, and do not believe that the cancer itself arises from the abnormal LCIS cells. An alternate view, which is generally accepted for DCIS, is that LCIS cells are intermediates in the progression to invasive cancer.
The pattern of early age of onset and multicentricity of neoplasms is reminiscent of heritable cancer predisposition syndromes, and suggests that LCIS may result from an inherited susceptibility. This hypothesis is supported by data showing that foci of LCIS are likely to be clonal (Lakhani et al, 1995) . Furthermore, there is evidence from systematic studies that both LCIS and invasive lobular carcinoma are associated with higher familial risks of breast cancer than other histological types (Claus et al, 1993; Cannon-Albright et al, 1994) . LCIS is not a manifestation of BRCA1 or BRCA2 mutations (BCLC, 1997) and therefore may be an indicator of a previously unrecognized cancer predisposition syndrome, in which the penetrance for invasive cancer is relatively low.
There are no known genes that confer susceptibility to LCIS. However, there is a-priori evidence suggesting that E-cadherin is a strong candidate for an LCIS predisposition gene. E-cadherin is a transmembrane adhesion protein with a central role in the maintenance of the normal architecture and function of epithelial cells (Takeichi, 1995) . Over 400 tumours from ten different tissue types have been screened for E-cadherin mutations (Berx et al, 1998) . Somatic mutations occur frequently in two histological subtypes: diffuse gastric carcinomas and lobular breast cancers. In lobular breast carcinomas, the E-cadherin mutations generally result in premature truncation of translation and are usually accompanied by loss of the wild-type allele (Berx et al, 1995 (Berx et al, , 1996 . This suggests that E-cadherin acts as a tumour suppressor gene. In LCIS, E-cadherin expression is almost always absent (Moll et al, 1993) , and somatic E-cadherin mutations together with loss of heterozygosity (LOH) of the wild-type allele have been identified . In two breast cancers, the same mutation was identified in the LCIS and invasive components, supporting the theory that LCIS is an invasive precursor . In contrast, somatic E-cadherin mutations have not been reported in either DCIS or invasive ductal breast carcinomas and E-cadherin expression is not absent in these neoplasms Berx et al, 1998) . Loss of E-cadherin has been demonstrated in LCIS adjacent to E-cadherin-positive invasive lobular cancers indicating that loss of E-cadherin is an important early step in the formation of LCIS. To our knowledge, the presence of constitutional E-cadherin mutations in individuals with LCIS has not been investigated. However, constitutional Ecadherin mutations that predispose to familial diffuse gastric cancer have been identified (Gayther et al, 1998; Guilford et al, 1998) . In order to examine whether constitutional alterations in Ecadherin predispose to LCIS we have analysed blood samples from 65 patients with LCIS for germline mutations in the gene.
PATIENTS AND METHODS

Patients
All individuals with a histologically proven diagnosis of LCIS that attended the Royal Marsden Hospital between 1971 and 1996 were invited to participate. Samples were obtained with informed consent and local ethical review board approval. EDTA-venous blood samples were obtained from 65 patients. DNA was extracted using a standard sucrose lysis protocol.
Methods
The full coding sequence and splice junctions of E-cadherin were screened for mutations using conformational specific gel electrophoresis (CSGE) (Ganguly et al, 1993) . Published oligonucleotide sequences were used to amplify each exon of the Ecadherin gene (including splice sites) by polymerase chain reaction (PCR) (Berx et al, 1995) . All samples with bandshifts detected by CSGE were sequenced in duplicate and in forward and reverse orientations after re-amplification of the appropriate exon from genomic DNA in the PCR. Purified PCR products were sequenced using ABI Ready Reaction Dye Terminator Cycle Sequencing Kit and the ABI 377 Prism sequencer.
RESULTS
DNA from 65 patients with a histologically proven diagnosis of LCIS was obtained. None of the patients had invasive cancer at the time of diagnosis of LCIS. The clinical details of the patients are shown in Table 1 . Seventeen of the patients had bilateral disease and 21 also had a diagnosis of DCIS. Twenty of the patients had a first-degree relative affected with invasive breast cancer, but only one had a family history highly suggestive of the inheritance of a dominantly acting breast cancer susceptibility gene. The full coding sequence and splice junctions of E-cadherin were screened for mutations in all samples. No pathogenic mutations were identified in any of the patients screened. Four polymorphic variants were detected in 29 of the patients ( Table 2 ). All were synonymous substitutions and have been previously reported (Berx et al, 1998) .
DISCUSSION
We have obtained DNA from 65 individuals with LCIS. Thirtytwo per cent of the patients studied had a family history of invasive breast cancer suggesting that LCIS confers a fourfold increase in breast cancer risk in first-degree relatives. Twenty-six per cent of patients had bilateral disease. These data are concordant with the hypothesis that a proportion of LCIS results from inherited predisposition and suggests that a LCIS susceptibility gene may also confer an elevated risk of invasive breast cancer. E-cadherin is mutated somatically at high frequency in LCIS, invasive lobular breast cancer and diffuse gastric cancer (Berx et al, 1998) . Constitutional predisposing E-cadherin mutations have recently been detected in familial gastric cancer pedigrees (Gayther et al, 1998; Guildford et al, 1998) . We have examined lymphocyte DNA from 65 individuals with LCIS, for germline alterations in E-cadherin. No disease-causing alterations were identified. This suggests that constitutional mutations in E-cadherin do not confer susceptibility to LCIS.
We cannot exclude the possibility that a minority of mutations have been missed, or cannot be detected by a PCR-based approach. However, under test conditions we have found this technique can detect all small insertions and deletions and 90% of single-base substitutions. Confirmation of the efficiency of this technique is that we were able to demonstrate a number of singlebase substitution polymorphisms within the gene. Therefore it is unlikely that we have failed to detect any coding mutations.
It is theoretically possible that constitutive mutations in Ecadherin are responsible for a few LCIS cases. However, based on the number of patients we have examined we can conclude with 95% probability that germline variation in E-cadherin does not account for more than 4% of cases of LCIS. The high frequency of somatic mutations in the E-cadherin gene in LCIS coupled with the recent finding that germline mutations in the gene can predispose to diffuse gastric cancer suggested that constitutional E-cadherin mutations might confer susceptibility to LCIS. The results presented indicate that this is very unlikely and that the majority of LCIS cases do not result from germline mutations in E-cadherin. However, the elevated incidence of bilateral LCIS and of invasive breast cancer in relatives, supports the hypothesis that a proportion of LCIS results from genetic susceptibility. The identity of this susceptibility gene is unknown, but may also be a low penetrance invasive breast cancer susceptibility gene.
Note added in proof
A frameshift mutation in exon 3 of E-cadherin has recently been reported in a patient with LCIS who had a strong family history of gastric cancer (Keller et al, 1999) .
